Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-045: Pembrolizumab vs Chemotherapy in Advanced Urothelial Cancer
NCT02256436Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2014
- Primary completion
- Sep 2016
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
A Phase 3 trial of pembrolizumab in urothelial carcinoma (UC), sponsored by Merck & Co.. Started Oct 2014; status: completed.
02
Drugs
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT02256436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02256436.